Brokers Issue Forecasts for BLFS Q4 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities researchers at Northland Capmk issued their Q4 2025 earnings per share estimates for shares of BioLife Solutions in a report released on Wednesday, January 8th. Northland Capmk analyst C. Byrnes expects that the medical equipment provider will earn $0.00 per share for the quarter. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.29) per share. Northland Capmk also issued estimates for BioLife Solutions’ FY2026 earnings at $0.10 EPS.

BLFS has been the subject of a number of other research reports. TD Cowen boosted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright cut their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Craig Hallum raised their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Benchmark reiterated a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, Northland Securities raised their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus price target of $29.43.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS opened at $26.61 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm has a fifty day moving average of $25.99 and a 200 day moving average of $24.29. The firm has a market cap of $1.23 billion, a PE ratio of -25.10 and a beta of 1.92. BioLife Solutions has a one year low of $14.50 and a one year high of $28.88.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, CEO Greef Roderick De sold 46,896 shares of BioLife Solutions stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $23.43, for a total value of $1,098,773.28. Following the sale, the chief executive officer now owns 414,958 shares in the company, valued at $9,722,465.94. The trade was a 10.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total value of $232,800.00. Following the transaction, the executive vice president now owns 317,716 shares of the company’s stock, valued at approximately $7,396,428.48. This represents a 3.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 113,129 shares of company stock worth $2,576,818 in the last three months. 2.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BLFS. Stifel Financial Corp lifted its stake in BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after acquiring an additional 670 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 748 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of BioLife Solutions by 5.8% in the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock valued at $296,000 after purchasing an additional 753 shares during the period. Mark Sheptoff Financial Planning LLC acquired a new position in shares of BioLife Solutions in the third quarter valued at approximately $28,000. Finally, Curi RMB Capital LLC increased its stake in BioLife Solutions by 0.5% during the 3rd quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock worth $10,565,000 after buying an additional 2,283 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.